The Mark Foundation for Cancer Research has selected four multi-institutional teams to receive Endeavor Awards totaling $12 million.
Each team, comprising researchers from 11 academic institutions across five countries, will receive $3 million over three years, according to an Oct. 7 news release.
Since 2017, the Mark Foundation for Cancer Research has provided more than $300 million in grants to researchers at more than 120 institutions in 18 countries, the release said.
Here are the four teams and their projects:
- Researchers at the Flanders Institute for Biotechnology in Belgium and Montreal-based McGill University will study why some colorectal cancers that spread to the liver develop a more aggressive growth pattern, including how fatty liver disease may drive that shift.
- Researchers at the University of North Carolina at Chapel Hill and Rochester, Minn.-based Mayo Clinic will test a drug that blocks the NLRP3 pathway, which the team previously linked to immunotherapy failure in advanced gastric and esophageal cancers. The Torrey Coast Foundation is co-funding the project.
- Researchers at New York City-based Icahn School of Medicine at Mount Sinai, Cambridge, Mass.-based Harvard University, New York City-based Columbia University and Ghent University in Belgium aim to reprogram immune cells that tumors co-opt for protection into active antitumor agents.
- Researchers at the AITHYRA Institute in Austria, the Swiss Federal Institute of Technology in Lausanne and Stanford (Calif.) University will design drugs that lock cancer-driving transcription factors into an inactive state, with a focus on treatment-resistant prostate, pancreatic, gastric and brain cancers.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
